ZARZA We are Zarza, the prestigious firm behind major projects in information technology.

FDA Approval: Datopotamab Deruxtecan for EGFR NSCLC

Lung Cancer Considered

18/07/2025 45 min

FDA Approval: Datopotamab Deruxtecan for EGFR NSCLC

Listen "FDA Approval: Datopotamab Deruxtecan for EGFR NSCLC"

Descargar episodio Ver en sitio original

Episode Synopsis

FDA Approval: Datopotamab Deruxtecan for EGFR NSCLC by IASLC

More episodes of the podcast Lung Cancer Considered

LCC in Greek: WCLC 2025 Highlights 10/10/2025

FDA Approval: Maintenance Lurbinectedin for SCLC 07/10/2025

LCC in Arabic: WCLC 2025 Highlights 03/10/2025

Lung Cancer Considered in Dutch: Targeting EGFR NSCLC 03/10/2025

Lung Cancer Considered: Targeting EGFR NSCLC 03/10/2025

LCC in Korean: WCLC 2025 Highlights 30/09/2025

IASLC Lung Cancer Considered: FDA Approval: Subcutaneous Immunotherapy 26/09/2025

LCC in Mandarin: WCLC 2025 Highlights with Experts from Taiwan 18/09/2025

LCC in Portuguese: WCLC 2025 Highlights 16/09/2025

LCC in Spanish: WCLC 2025 Through a Junior Faculty Lens 11/09/2025

Ver todos los episodios